Disease The intractable diseases designated by MHLW, Japan
Diseases : 348 - Clinical trials : 43,690 / Drugs : 27,527 - ( DrugBank : 2,441 ) / Drug target genes : 714 - Drug target pathways : 315
| ID | Disease name [Group] | Clinical trial Phase 1 / 2 / 3 / 4 | Drug [ DrugBank ] | Target gene Target pathway | Domestic patients Med expenses recipients, FY2024 (corrected) |
|---|---|---|---|---|---|
| 66 | IgA nephropathy [Kid] 💬 "IgA nephritis", "Berger disease", "IgA-IgG nephropathy", "Glomerulonephritis" | 407 407 trials | 21 / 129 / 123 / 43 💬 | 342 342 drugs [ 73 73 drugs ] | 40 40 genes 146 pathways | 15355 15,355 patientsAge distribution
|
| 67 | Polycystic kidney disease [Kid] 💬 "PKD", "PCKD", "Polycystic kidney", "Autosomal dominant polycystic kidney disease", "Autosomal dominant PKD", "ADPKD", "Autosomal recessive polycystic kidney disease", "Autosomal recessive PKD", "ARPKD" | 251 251 trials | 23 / 78 / 100 / 15 💬 | 278 278 drugs [ 69 69 drugs ] | 97 97 genes 182 pathways | 13912 13,912 patientsAge distribution
|
| 109 | Atypical hemolytic uremic syndrome [Kid] 💬 "Atypical HUS", "aHUS" | 130 130 trials | 0 / 32 / 49 / 6 💬 | 44 44 drugs [ 5 5 drugs ] | 2 2 genes 11 pathways | 112 112 patientsAge distribution
|
| 218 | Alport syndrome [Kid] 💬 "Glomerulonephritis" | 47 47 trials | 3 / 21 / 9 / 3 💬 | 49 49 drugs [ 23 23 drugs ] | 8 8 genes 46 pathways | 326 326 patientsAge distribution
|
| 219 | Galloway-Mowat syndrome [Kid] 💬 | 0 - | 0 - | 0 - | 2 2 patientsAge distribution
|
| 220 | Rapidly progressive glomerulonephritis [Kid] 💬 "RPGN", "Necrotizing crescentic glomerulonephritis", "NCGN", "Glomerulonephritis" | 0 - | 0 - | 0 - | 1440 1,440 patientsAge distribution
|
| 221 | Anti-glomerular basement membrane disease [Kid] 💬 "Goodpasture syndrome", "Glomerulonephritis" | 9 9 trials | 0 / 3 / 1 / 0 💬 | 12 12 drugs [ 4 4 drugs ] | 2 2 genes 22 pathways | 458 458 patientsAge distribution
|
| 222 | Primary nephrotic syndrome [Kid] 💬 "Nephrotic syndrome", "Glomerulonephritis", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Crescentic glomerulonephritis", "CGN", "CrGN", "Endocapillary proliferative glomerulonephritis" | 576 576 trials | 44 / 151 / 117 / 86 💬 | 519 519 drugs [ 130 130 drugs ] | 108 108 genes 219 pathways | 14333 14,333 patientsAge distribution
|
| 223 | Primary membranoproliferative glomerulonephritis [Kid] 💬 "Primary MPGN", "Primary membranoproliferative glomerulonephritis type I", "Primary MPGN I", "Primary membranoproliferative glomerulonephritis type III", "Primary MPGN III", "Membranoproliferative glomerulonephritis", "Glomerulonephritis", "C3 glomerulonephritis", "C3 glomerulopathy", "IC-MPGN", "MPGN" | 243 243 trials | 8 / 62 / 49 / 17 💬 | 296 296 drugs [ 84 84 drugs ] | 46 46 genes 169 pathways | 440 440 patientsAge distribution
|
| 224 | Purpura nephritis [Kid] 💬 "Henoch-Schönlein purpura nephritis", "HSPN" | 19 19 trials | 1 / 3 / 1 / 5 💬 | 42 42 drugs [ 19 19 drugs ] | 16 16 genes 64 pathways | 1237 1,237 patientsAge distribution
|
| 225 | Congenital nephrogenic diabetes insipidus [Kid] 💬 "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus" | 19 19 trials | 3 / 5 / 0 / 2 💬 | 56 56 drugs [ 21 21 drugs ] | 33 33 genes 67 pathways | 59 59 patientsAge distribution
|
| 226 | Interstitial cystitis with Hunners ulcer [Kid] 💬 "Interstitial cystitis" | 177 177 trials | 15 / 67 / 28 / 9 💬 | 208 208 drugs [ 60 60 drugs ] | 87 87 genes 148 pathways | 1161 1,161 patientsAge distribution
|
| 315 | Nail-Patella syndrome [Kid] 💬 "LMX1B-associated nephropathy" | 0 - | 0 - | 0 - | 10 10 patientsAge distribution
|
| 335 | Nephronophthisis [Kid] 💬 "NPHP", "NPH" | 2 2 trials | 0 / 0 / 0 / 0 💬 | 3 3 drugs [ 0 - ] | 0 - | 27 27 patientsAge distribution
|
